Ovid Therapeutics (Ovid Therapeutics) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 01, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Ovid Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Ovid Therapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Ovid Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ovid Therapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.

Ovid Therapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ovid Therapeutics (Ovid Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

1OT:Germany

Address

441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001

Website

https://www.ovidrx.com

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Executives

Jason Tardio	officer: Chief Commercial Officer	1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald	director	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit	officer: CMO and PMO	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole	director	200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona	officer: Chief Business Officer	500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin	director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone	officer: SVP, General Counsel	1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein	director	C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc	10 percent owner	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward	officer: SVP and General Counsel	C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly	officer: VP, Finance & Corp. Controller	20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854